$GSK has been mentioned 40 times over the past 12 months by three distinct FinTwit voices, with the first mention appearing on September 15, 2025. The most active voice discussing the company is @jacobplieth (Jacob Plieth) with 55 mentions, followed by @adamfeuerstein (Adam Feuerstein ✡️) with 8 mentions, and @nezih_gokay (Nezih Gökay) with 1 mention. The biotech category dominates discussion of $GSK among these voices.

As of July 2026, recent conversation has focused on GSK's decision to shelve development of camlipixant following disappointing Phase 3 study results. This development is significant given that GSK acquired the drug from Bellus Health in 2023 for $2 billion. @adamfeuerstein documented this clinical setback on July 17, 2026, while @jacobplieth remarked on the timing of this news relative to positive business development commentary from Jefferies published the same day.